Suppr超能文献

补充镁和减肥对非酒精性脂肪性肝病患者肝酶的影响。

The effect of magnesium supplementation and weight loss on liver enzymes in patients with nonalcoholic fatty liver disease.

作者信息

Karandish Majid, Tamimi Mahtab, Shayesteh Ali Akbar, Haghighizadeh Mohammad Hosein, Jalali Mohammad Taha

机构信息

Nutrition and Metabolic Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Department of Nutritional science, Arvand International Division, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

出版信息

J Res Med Sci. 2013 Jul;18(7):573-9.

Abstract

BACKGROUND

There have been few studies to examine the effect of magnesium (Mg) supplementation on liver enzymes. The aim of this study was to evaluate the effect of Mg supplementation and weight loss on liver enzymes, lipid profile, and fasting blood sugar in patients with nonalcoholic fatty liver disease (NAFLD).

MATERIALS AND METHODS

This study was a double-blind, placebo-controlled, randomized clinical trial. Ultrasonography was used to diagnose fatty liver in patients with alanine aminotransferase (ALT) ≥ 40 U/L and without other hepatic diseases. A total of 68 participants (18-59 years) with NAFLD were randomly divided into two groups to receive either Mg supplement (350 mg elemental Mg per day) or placebo for 90 days. At baseline and at the end of the intervention serum ALT, aspartate aminotransferase (AST), alkaline phosphatase (ALP), total cholesterol (TCHO), high-density lipoprotein cholesterol (HDL-C), triglyceride (TG), blood sugar and serum insulin, and Mg levels were measured in fasting state. Low-density lipoprotein cholesterol (LDL-C) and insulin resistance (IR) were calculated using Friedewald formula and homeostasis model assessment of insulin resistance (HOMA-IR), respectively. All participants received lifestyle recommendations including low calorie diet and physical activity.

RESULTS

Significant decreases within the intervention and placebo groups were observed in ALT (57.00 (25) to 41.82 ± 19.40 U/L, P = 0.000; 68.50 ± 26.96 to 40.17 ± 19.40 U/L, P = 0.000 in Mg and placebo groups, respectively). Similar significant decreases were observed in AST and fasting serum insulin within the study groups. The decrease in weight was also significant in both groups (91.05 ± 13.77 to 87.60 ± 14.37 kg and 94.59 ± 16.85 to 91.45 ± 16.39 kg in Mg and placebo groups, respectively). LDL-C and TCHO were decreased significantly in placebo group but not in the intervention group. Serum Mg was increased significantly in the intervention group. No statistically significant differences were observed between the two study groups at baseline and after intervention.

CONCLUSION

According to the findings of this study, Mg supplement does not affect liver enzymes but weight loss may have an important role in improving fatty liver disease.

摘要

背景

很少有研究探讨补充镁(Mg)对肝酶的影响。本研究的目的是评估补充镁和体重减轻对非酒精性脂肪性肝病(NAFLD)患者肝酶、血脂谱和空腹血糖的影响。

材料与方法

本研究为双盲、安慰剂对照、随机临床试验。超声检查用于诊断丙氨酸氨基转移酶(ALT)≥40 U/L且无其他肝脏疾病的患者是否患有脂肪肝。共有68名年龄在18至59岁之间的NAFLD参与者被随机分为两组,分别接受镁补充剂(每天350毫克元素镁)或安慰剂,为期90天。在基线和干预结束时,测量空腹状态下的血清ALT、天冬氨酸氨基转移酶(AST)、碱性磷酸酶(ALP)、总胆固醇(TCHO)、高密度脂蛋白胆固醇(HDL-C)、甘油三酯(TG)、血糖和血清胰岛素以及镁水平。分别使用Friedewald公式和胰岛素抵抗稳态模型评估(HOMA-IR)计算低密度脂蛋白胆固醇(LDL-C)和胰岛素抵抗(IR)。所有参与者均接受包括低热量饮食和体育活动在内的生活方式建议。

结果

干预组和安慰剂组的ALT均显著下降(镁组从57.00(25)降至41.82±19.40 U/L,P = 0.000;安慰剂组从68.50±26.96降至40.17±19.40 U/L,P = 0.000)。研究组内AST和空腹血清胰岛素也有类似的显著下降。两组体重下降也均显著(镁组从91.05±13.77降至87.60±14.37 kg,安慰剂组从94.59±16.85降至91.45±16.39 kg)。安慰剂组的LDL-C和TCHO显著下降,但干预组未下降。干预组血清镁显著升高。两个研究组在基线和干预后均未观察到统计学上的显著差异。

结论

根据本研究结果,补充镁对肝酶无影响,但体重减轻可能在改善脂肪性肝病中起重要作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44c0/3897024/f04c27d564d4/JRMS-18-573-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验